Gabriel Ocana Santero

Working on next-generation neurotherapeutics

Co-founder

Exin Therapeutics· Winter 2025🇺🇸 South San Francisco, California, United States

in LinkedIn 𝕏 @OcanaSantero

2025Co-founder· Exin Therapeutics

Founder · since 2025

Company

Exin Therapeutics

Role

CEO and Co-founder

current

Stage

—

no public source

Raised

—

no public source

Based

San Francisco Bay Area

current

Founder / co-founder — the company's markEmployee / research role

Source: LinkedIn work history

Profile coverage5 of 7 · missing posts, contact

Exin Therapeutics

AI drug discovery platform for neurotherapeutics

Winter 2025

Experience

Career

Exin Therapeutics
Co-founder
CEO and Co-founder · San Francisco Bay Area · 2025 – Present
2025
Serotonin and BEYOND
Serotonin and Beyond Early Stage Researcher · Oxford, England, United Kingdom · 2021 – 2024
2021
Gatsby Computational Neuroscience Unit
NeuroAI Research Internship · London, England, United Kingdom · 2023
2023
Fundación "la Caixa"
Postgraduate Studies' Fellowship Holder · Оксфорд · 2020 – 2021
2020
Centro de Biología Molecular Severo Ochoa, CBMSO
Research Intern · Madrid y alrededores · 2020
2020
Karolinska Institutet
Research Intern · Stockholm, Sweden · 2019
2019
Medical University of Vienna
Research Intern · Austria · 2018
2018

Bio

Neuroscientist with a background in biochemistry and research on gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. Earned MSc in Neuroscience and PhD in Pharmacology at Oxford Uni, focusing on neurodevelopment and the effects of SSRI anti-depressants on early patterns of neural activity. Used neuroAI models at the Gatsby Unit (UCL) to study serotonin’s role in cognition. Currently developing gene therapies for neurological conditions.